Neuromuscular aspects of Duchenne Muscular Dystrophy

Parent JONTHEFIGHT.
Project ENDOUCHENNE.
Muscular
Dystrophy

Jena Krueger August 21, 2022

Conflict of interest

I am currently or was previously a principal investigator for funded pharmaceutical trials with Avexis/Novartis*, Scholar Rock Inc, Fibrogen and Genentech

This presentation may include non-FDA approved use of medication and treatment in pediatric neuromuscular disorders


^{*} Published work at least partially produced utilizing medical writers supported by pharmaceutical company

Objectives

- Define Duchenne Muscular Dystrophy
- Discuss the multidisciplinary care model

History¹

- Described by Meryon, 1852 and Little in 1853
- 1861 Duchenne established diagnostic criteria
- Becker Muscular Dystrophy described in 1955
- DMD gene mapped on Xp21



Duchenne Muscular Dystrophy

- Absent or deficient dystrophin
- Dystrophin = protein responsible for strength, stability, function of muscle fibers²


DMD gene³

| 1 | $ \rangle$ | 2 | 3 | 4 | 5 | 6 < | 7 | 8 | 9 | 10 | 11 < | |
|----|-------------|----|------|----|--------|----------------|------|------|------|------|------|----|
| (1 | 2 | 13 | 14 | 15 | 16 | 17 | (18 | 19 | 20 | 21 | 22 | |
| 2 | 3 | 24 | 25 | 26 | 27 | 28 | 2 | 9 | 30 | 31 | 32 | 33 |
| 3 | 4 | 35 | 36 | 37 | 38 | 39 | 40 |) | 41 | 42 | 43 < | 44 |
| 4 | 5 < | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 < | 55 | |
| 5 | 6 < | 57 | 58 | 59 | 60 6 | $1 > \epsilon$ | 62 | 63 | 64 | 65 | | |
| 6 | 6 | 67 | 68 < | 69 | 70 < 7 | /1 🤇 | 72 🤇 | 73 (| 74 < | 75 | | |
| 7 | 6 | 77 | 78 | 79 | | | | | | | | |



Genetics

Chromosome to Gene to Protein




Greenwood Genetic Center




Genetics

Types of Gene Mutations



Greenwood Genetic Center





Multidisciplinary Clinic Visit

- Height/Weight
- Neurology
- Pulmonary
- Physical Therapy
- Social Work
- Genetics
- Treatment

- Cardiology EKG, ECHO/cMRI
- Endocrine DEXA / X-Ray
- Orthopedics
- Rehabilitation
- Durable Medical Company
- Orthotics

- Speech therapy
- Occupational Therapy
- Neuropsych
- Palliative Care







Google images

Neurology's Role²

- Evaluate each patient individually
- Establish baseline and trajectory with validated assessment tools
- Management
 - Medications, research options
 - Respiratory and cardiac technology
 - Surgical options: scoliosis, contractures
- Coordinate multidisciplinary team



Treatment²

- Steroids
- Approved therapies
 - Exon skipping
- Treating symptoms (constipation, sleep, ect)
- Research options
- PT and Stretching
- Orthotics



Steroids

- Prednisone
- Deflazacort (Emflaza)



Timeline and dosing

Initial discussion

Discuss use of steroids with family



Begin steroid regimen

- · Before substantial physical decline
- After discussion of side-effects
- · After nutrition consultation



Recommended starting dose

- Prednisone or prednisolone 0-75 mg/kg per day
 OR
- Deflazacort 0-9 mg/kg per day



Dosing changes

If side-effects unmanageable or intolerable

- Reduce steriods by 25-33%
- · Reassess in 1 month

If functional decline

- Increase steroids to target dose per weight on the basis of starting dose
- Reassess in 2-3 months



Use in non-ambulatory stage

- Continue steroid use but reduce dose as necessary to manage side-effects
- Older steroid-naive patients might benefit from initiation of a steroid regimen

Cautions

Adrenal insufficiency

Patient and family education

 Educate on signs, symptoms, and management of adrenal crisis

Prescribe intramuscular hydrocortisone for administration at home

- 50 mg for children aged <2 years old
- 100 mg for children aged ≥2 years old and adults
 Stress dosing for patients taking >12 mg/m² per day of prednisone/deflazacort daily
- Might be required in the case of severe illness, major trauma, or surgery
- Administer hydrocortisone at 50–100 mg/m² per day

Do not stop steroids abruptly

- Implement PJ Nicholoff steroid-tapering protocol²⁹
- Decrease dose by 20–25% every 2 weeks
- Once physiological dose is achieved (3 mg/m² per day of prednisone or deflazacort) switch to hydrocortisone 12 mg/m² per day divided into three equal doses
- Continue to wean dose by 20–25% every week until dose of 2-5 mg hydrocortisone every other day is achieved
- After 2 weeks of dosing every other day, discontinue hydrocortisone
- Periodically check morning CRH-stimulated or ACTH-stimulated cortisol concentration until HPA axis is normal
- Continue stress dosage until HPA axis has recovered (might take 12 months or longer)

Steroids

- Able to walk longer
- Arms stay stronger longer
- Helps to keep breathing muscles strong
- Avoid scoliosis surgery
- Delays cardiomyopathy (heart dysfunction)
- Improves survival
- BUT ... steroids have side effects too

Prednisone

Deflazacort

Preferred by US insurance More like to cause cataracts
More behavioral side effects Decreased height
More like to cause diabetes More osteopenia
More weight gain

Both improve strength (compared to placebo)
*deflazacort may be more effective at delaying loss of
muscle strength, motor function
Daily and weekend only regimens were both effective



Preparing for your appointment

- Bring snacks
- Bring activities for your child
- PPMD Care Checklists

www.parentprojectmd.org

- → Care
- → Duchenne Care Guidelines





Monitoring

- Height, Weight, BP
- QOL
- New symptoms or concerns
- Labs
- Pulmonary function testing
- EKG / ECHO



Monitoring

- PT assessment every 6 months
 - Range of motion, strength
 - North Star Ambulatory Assessment, timed function tests (6MWT)
 - BayleyIII and Griffiths mental development in infants
 - Brooke upper extremity, Egan Klassifikation in non-ambulatory

After your appointment

- Daily Stretching !! 4-6 times per week
- AFO
 - Night while ambulatory, day if non-ambulatory
- Submaximal, aerobic exercise (swimming, cycling)
 - Avoid high-resistance, over exertion

References

- 1. BT Darras, CC Menache-Starobinski, V Hinton, L Kunkel. "Dystrophinopathies" ch 30, p551-592. BT Darras, H Royden Jones Jr., MM Ryan and DC De De Vivo (Eds): Neuromuscular disorders of Infancy, Childhood and Adolescence, 2nd ed.
- 2. DJ Birnkrant, K Bushby, CM Bann, et al "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine and gastrointestinal and nutritional management" Lancet Neurology 2018
- 3. <u>www.parentprojectmd.org</u>
- 4. DJ Birnkrant, K Bushby, CM Bann, et al "Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, orthopedic management" Lancet Neurology 2018
- 5. DJ Birnkrant, K Bushby, CM Bann, et al "Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care and transitions of care across the lifespan" Lancet Neurology 2018
- 6. WD Biggar, A Skalsky, CM McDonald "Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy". Journal of Neuromuscular Diseases 9 (2022) 463-476

